Powered by

Ember Therapeutics Enters Into Agreement to Divest OP-1 Portfolio Program to Viscogliosi Brothers, LLC

Aug 16, 2018 - PR Newswire

 Ember Therapeutics, Inc.,a clinical stage biopharmaceutical company focused on the clinical application of Bone Morphogenetic Protein-7 (BMP-7), announced today that it has entered into a letter of intent withViscogliosi Brothers, LLC  (VB), a private equity investment firm focused on developing innovative neuromusculoskeletal technologies,  for the sale of its OP-1 product family and related assets, which includes OP-1 Implant, OP-1 Putty, Opgenra and Osigraft for use in orthopaedic bone a...